Abnormalities of retinal metabolism in diabetes or experimental galactosemia VIII. Prevention by aminoguanidine

Reference

• Engerman RL, Kern TS. Experimental galactosemia pro-duces diabetic-like retinopathy. Diabetes. 1984;33:97–100.
   PubMed Web of Science ®Google Scholar
• Kern TS, Engerman RL. Comparison of retinal lesions in alloxan-diabetic rats and galactose-fed rats. Curr Eye Res. 1994;13:863–867.
   PubMed Web of Science ®Google Scholar
• Kador PF, Akagi Y, Takahashi Y et al. Prevention of retinal vessel changes associated with diabetic retinopathy in galactose-fed dogs by aldose reductase inhibitors. Arch Ophthalmol. 1990;108:1301–1309.
   PubMed Web of Science ®Google Scholar
• Stitt AW, M LY, Gardiner TA et al. Advanced glycation end products (AGEs) co-localize with AGE receptors in the retinal vasculature of diabetic and of AGE-infused rats. Am J Pathol. 1997;150:523–531.
   PubMed Web of Science ®Google Scholar
• Ishii H, Jirousek MR, Koya D et al. Amelioration of vascular dysfunctions in diabetic rats by an oral PKC inhibitor. Science. 1996;272:728–731.
   PubMed Web of Science ®Google Scholar
• Kowluru RA, Jirousek MR, Stramm LE et al. Abnor-malities of retinal metabolism in diabetes or experimental galactosemia. V. Relationship between protein kinase C and ATPases. Diabetes. 1998;47:464–469.
   Google Scholar
• Armstrong D, Abdella N, Salman A et al. Relationship of lipid peroxides to diabetic complications. J Diab Comp. 1992;6:116–122.
   Google Scholar
• Kowluru RA, Kern TS, Engerman RL. Abnormalities of retinal metabolism in diabetes or experimental galac-tosemia. IV. Antioxidant defense system. Free Rad Biol Med. 1996;22:587–592.
   Google Scholar
• Yan SD, Schmidt AM, Anderson GM et al. Enhanced cellular oxidant stress by the interaction of advanced glycation end products with their receptors/binding pro-teins. J Biol Chem. 1994;269:9889–9897.
   PubMed Web of Science ®Google Scholar
• Yang S-W, Vlassara H, Peten EP et al. Advanced gly-cation end products up-regulate gene expression found in diabetic glomerular disease. Proc Natl Acad Sci USA. 1994;91:9436–9440.
   PubMed Web of Science ®Google Scholar
• Zimmerman GA, Meistrell III M, Bloom 0 et al. Neu-rotoxicity of advanced glycation endproducts during focal stroke and neuroprotective effects of aminoguanidine. Proc Natl Acad Sci USA. 1995;92:3744–3748.
   Google Scholar
• Brownlee M, Vlassara H, Kooney A et al. Aminoguani-dine prevents diabetes-induced arterial wall protein cross linking. Science. 1986;232:1629–1632.
   PubMed Web of Science ®Google Scholar
• Nicholls K, Mandell TE. Advanced glycosylation end-products in experimental murine diabetic nephropathy: Effect of islet isografting and of aminoguanidine. Lab Invest. 1989;60:486–491.
   PubMed Web of Science ®Google Scholar
• Picard S, Parthasarathy S, Fruebis J etal. Aminoguanidine inhibits oxidative modification of low density lipoprotein and the subsequent increase in uptake by macrophage scavenger receptors. Proc Soc Natl Acad Sci USA. 1991; 89:6876–6880.
   Google Scholar
• Ou P, Wolff SP. Aminoguanidine: A drug proposed for prophylaxis in diabetes inhibits catalase and generates hydrogen peroxide in vitro. Biochem Pharm. 1993;46: 1139–1144.
   PubMed Web of Science ®Google Scholar
• Tilton RG, Chang K, Hasan KS et al. Prevention of dia-betic vascular dysfunction by guanidines. Inhibition of nitric oxide synthase versus advanced glycation end-product formation. Diabetes. 1993;42:221–232.
   Google Scholar
• Corbett JA, Tilton RG, Chang K etal. Aminoguanidine, a novel inhibitor of nitric oxide formation, prevents dia-betic vascular dysfunction. Diabetes. 1992;41:552–556.
   Google Scholar
• Kihara M, Schemlzer JD, Poduslo JF et al. Aminoguani-dine effects on nerve blood flow, vascular permeability, electrophysiology, and oxygen free radicals. Proc Natl Acad Sci USA. 1991;88:6107–6111.
   PubMed Web of Science ®Google Scholar
• Hammes H-P, Martin S, Federlin K et al. Aminoguanidine treatment inhibits the development of experimental dia-betic retinopathy. Proc Natl Acad Sci USA. 1991;88: 11555–11558.
   PubMed Web of Science ®Google Scholar
• Kern TS, Tang J, Mizutani M et al. Response of capillary cell death to aminoguanidine predicts the development of retinopathy: Comparison of diabetes and galactosemia. Invest Ophthal Vis Sci. 2000; in press.
   Google Scholar
• Jain SK, Abreo K, Duett J et al. Lipofuscin products, lipid peroxides and aluminum accumulation in red blood cells of hemodialyzed patients. Am J Nephrol. 1995;5: 306–311.
   Web of Science ®Google Scholar
• Kowluru RA, Engerman RL, Kern TS. Abnormalities of retinal metabolism in diabetes or experimental galac-tosemia VI. Comparison of retinal and cerebral cortex metabolism, and effects of antioxidant therapy. Free Rad Biol Med. 1999;26:371–378.
   Google Scholar
• Kern TS, Kowluru R, Engerman RL. Abnormalities of retinal metabolism in diabetes or galactosemia. ATPases and glutathione. Invest Ophthal Vis Sci. 1994;35:2962–2967.
   PubMed Web of Science ®Google Scholar
• Wolff DJ, Lubeskie A. Aminoguanidine is an isoform-selective, mechanism-based inactivator of nitric oxide synthase. Arch Biochem Biophys. 1995;316:290–301.
   PubMed Web of Science ®Google Scholar
• Bryk R, Wolff DJ. Mechanism of inducible nitric oxide synthase inactivation by aminoguanidine and L-N6-(1-iminoethyl) lysine. Biochemistry. 1998;37:4844–4852.
   PubMed Web of Science ®Google Scholar
• Xia P, Inoguchi T, Kern TS et al. Characterization of the mechanism for the chronic activation of DAG-PKC pathway in diabetes and hypergalactosemia. Diabetes. 1994;43:1122–1129.
   PubMed Web of Science ®Google Scholar
• Jiang Z-Y, Woollard ACS, Wolff SP. Hydrogen peroxide production during experimental protein glycation. FEBS Letters. 1990;268:69–71.
   Google Scholar
• Giardino I, Fard AK, Hatchell DL et al. Aminoguanidine inhibits reactive oxygen species formation, lipid peroxi-dation, and oxidant-induced apoptosis. Diabetes. 1998;47: 1114–1130.
   PubMed Web of Science ®Google Scholar
• Agardh CD, Agardh E, Hultberg B et al. The glutathione levels are reduced in Goto-Kakizaki rat retina, but are not influenced by aminoguanidine treatment. Current Eye Res. 1998;17:251–256.
   PubMed Web of Science ®Google Scholar
• Maree A, Peer G, Iaina A et al. Nitric oxide in strepto-zotocin diabetic rats. Clinical Science. 1996;90:379–384.
   Web of Science ®Google Scholar
• Stevens MJ, Dananberg J, Feldman EL et al. The linked roles of nitric oxide, aldose reductase and, (Na,K)-ATPase in the slowing of nerve conduction velocity in streptozoto-cin diabetic rats. J Clin Invest. 1994;94:853–859.
   PubMed Web of Science ®Google Scholar
• Schmetterer L, Findl 0, Fasching P et al. Nitric oxide and ocular blood flow in patients with IDDM. Diabetes. 1997;653–658.
   Google Scholar
• Roth S. Role of nitric oxide in retinal cell death. Clin Neurosci. 1997;4:216–223.
   PubMedGoogle Scholar
• do Carmo A, Lopes C, Santos M et al. Nitric oxide syn-thase activity and L-arginine metabolism in the retinas from streptozotocin-induced diabetic rats. Gen Pharmacol. 1998;30:319–324.
   PubMedGoogle Scholar
• Chakravarthy U, Hayes RG, Stitt AW et al. Constitutive nitric oxide synthase expression in retinal vascular endo-thelial cells is suppressed by high glucose and advanced glycation end products. Diabetes. 1998;47:945–952.
   PubMed Web of Science ®Google Scholar
• Stauble B, Boscoboinik D, Tasinato A et al. Modulation of activator protein-1 (AP-1) transcription factor and protein kinase C by hydrogen peroxide and D-a-toco-pherol in vascular smooth muscles. Eur J Biochem. 1994; 226:393–402.
   PubMedGoogle Scholar
• Mene P, Pascale C, Teti A et al. Effects of advanced glycation end products on cytosolic Ca2+ signaling of cultured human mesangial cells. J Am Soc Nephrol. 1999; 7:1478–1486.
   Google Scholar
• Bursell SE, Takagi C, Clermont AC et al. Specific retinal diacylglycerol and protein kinase C beta isoform modu-lation mimics abnormal retinal hemodynamics in diabetic rats. Invest Ophthal Vis Sci. 1997;38:2711–2720.
   PubMed Web of Science ®Google Scholar